| Bioactivity | TTT 3002 is a potent and orally active FLT3 inhibitor. TTT 3002 potently inhibits FLT3 phosphorylation by activating mutations at residue D835, with an IC50 of 0.2 nM. TTT 3002 can be used for AML (acute myeloid leukemia) research[1]. |
| Invitro | TTT 3002 下调 Molm14 和 MV4-11 细胞中的 FLT3 磷酸化(pFLT3)[1]。TTT 3002 诱导细胞周期停滞，随后显著诱导凋亡[1]。 Western Blot Analysis[1] Cell Line: |
| In Vivo | TTT 3002 (6 mg/kg，口服灌胃，每天两次，持续 2 至 4 周) 在体内对几种 FLT3/ITD 相关 AML 小鼠肿瘤模型有效，且毒性极小[1]。TTT 3002 (6 mg/kg，口服灌胃，单次) 可被迅速吸收，具有双相最大血清浓度 (Cmax) 随后是单指数衰减[1]。 Animal Model: |
| Name | TTT 3002 |
| CAS | 871037-95-5 |
| Formula | C27H23N5O3 |
| Molar Mass | 465.50 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ma H, et al. TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo. Blood. 2014 Mar 6;123(10):1525-34 |